Anidulafungin versus fluconazole for invasive candidiasis.

By A. Reboli, C. Rotstein, P. Pappas, S. Chapman, D. Kett, Deepali Kumar, R. Betts, M. Wible, B. Goldstein, J. Schranz and 2 more. New England Journal of Medicine, 2007

861 citations recorded by the source corpus.

Subfields: Epidemiology, Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/0d2bf48f4d2da242faf035eafc2477688d02281d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. D. Kontoyiannis
2. T. Walsh
3. Trish Perl
4. Thierry Calandra
5. E. Anaissie
6. M. Pfaller
7. D. Diekema

In Infectious Diseases

1. D. Kontoyiannis
2. Trish Perl
3. E. Anaissie
4. M. Pfaller
5. D. Diekema

Citations in the corpus

• Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America (2009, background): “Fluconazole remains standard therapy for selected patients with candidemia, on the basis of abundant data from welldesigned clinical trials [27, 28, 53, 79].”
• Diagnosis and Management of Complicated Intra-Abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America (2010, neutral): “This observation, coupled with the common use of fluconazole prophylaxis in the intensive care unit, suggests empiric use of echinocandins (caspofungin, anidulafungin, and micafungin) [111–115].”
• Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. (2012, background): “Reboli et al 2007 [43] (245; 2003–2004) Anidulafungin 100 mg/d vs fluconazole 400 mg/d Randomized, double blinded Candidemia or invasive candidiasis Pregnancy $14 d after last positive blood culture Receipt of $1 d of antifungal drug and document fungal infection Clinical and microbiologic success a”
• Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection: 2009 Update by the Infectious Diseases Society of America (2009, background): “For empirical treatment of suspected catheter-related candidemia, use an echinocandin or, in selected patients, fluconazole A-II [186, 187, 194, 260] D ow naded rom http/academ ic.”
• Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). (2010, result): “Not surprisingly, invasive candidiasis was the most common IFI in each organ transplant type except among lung transplant recipients, and it was associated with a high overall mortality, similar to that seen in recent treatment trials of candidemia and other forms of invasive candidiasis [26–28].”
• Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. (2016, background): “in randomized, comparative clinical trials [24–28, 31, 32].”
• ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients (2016, background): “Fifteen reported primary results from clinical trials.(5-11,13-17,19,20) One publication analyzed results of a subgroup of cancer patients from a previously published trial.”